骨生物衍生材料复合人骨髓间充质干细胞异位成骨的实验研究  

Experimental Studies on Ectopic Osteogenesis by Seeding Human Mesenchymal Stem Cell on Human Natural Bone Derived Scaffold Materials

作　　者：康非吾[1] 唐休发[2] 温玉明[2] 吴正华[3] 黄欣[2] 

机构地区：[1]同济大学附属口腔医院口腔颌面外科,上海200072 [2]四川大学华西口腔医院口腔颌面-头颈肿瘤外科,四川成都610041 [3]山东大学齐鲁医院口腔颌面外科,山东济南250012

出　　处：《华西口腔医学杂志》2006年第4期357-361,共5页West China Journal of Stomatology

基　　金：同济大学科技发展基金资助项目(20041876);上海市卫生局科技发展基金资助项目(044106)

摘　　要：目的探讨骨髓间充质干细胞(MSCs)复合骨生物衍生材料异位成骨的可行性和成骨能力。方法将人骨生物衍生材料脱蛋白骨和脱钙骨在体外与人骨髓MSCs复合培养后,植入裸鼠背部左侧皮下。右侧皮下植入单纯生物衍生材料作为对照。于术后2,4,10周各时间点处死动物行大体标本、组织学观察,碱性磷酸酶(ALP)活性检测,比较其成骨能力。结果两种材料脱蛋白骨和脱钙骨均有异位成骨能力,随着植入时间的延长,新骨形成量逐渐增多,表现为软骨化成骨;对照组无成骨现象。ALP活性检测结果显示实验组随着时间的延长,ALP活性显著升高(P<0.05),而在相同各时间点比较,脱蛋白骨的ALP活性明显高于脱钙骨(P<0.05)。结论人骨生物衍生材料脱蛋白骨及脱钙骨和人骨髓MSCs可作为理想的支架材料和种子细胞应用于骨组织工程;且作为支架材料脱蛋白骨优于脱钙骨。Objective To investigate the ectopic ostoogenesis potential of human natural bone derived material combined with human bone marrow mesenchymal stem ceils （MSCs）. Methods Cell-scaffold complexes were implanted subcutaneously into the left back of the nude mice, and human natural bone derived material were implanted into the right back as control group. The mice were killed respectively on the postoperative 2 weeks, 4 weeks and 8 weeks. The macroscopic, histopathological, alkaline phosphatase （ALP） activity assay methods were performed to assess the ectopic osteogenesls potential. Results The cartilaginous ostoogenesis were observed in both depreteinated bone and decalcified bone, and the more new bone tissue formed gradually as the time went by after implantation. ALP activity become stronger followed with the time （P〈0.05）, and compared with the decalcified bone, depreteinated bone displayed stronger ALP activity （P〈0.05）. Conclusion The MSCs and human natural bone derived material can be used as good seed ceils and scaffold materials respectively to construct tissue-engineered bone, and as the scaffold material, deproteinated bone has better osteogenesis ability than decalcffed bone.

关 键 词：骨髓间充质干细胞 骨生物衍生材料 骨组织工程 

分 类 号：R318.08[医药卫生—生物医学工程]